Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn's disease.1 The study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission at Week 12 as well as endoscopic response at Week 12. All remaining multiplicity-controlled secondary endpo
In the last year, many Johnson & Johnson ( NYSE:JNJ ) insiders sold a substantial stake in the company which may have...
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.